News
IBIO
0.3119
-7.28%
-0.0245
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Benzinga · 05/23 07:57
iBio to Participate in the H.C. Wainwright Global Investment Conference
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today announced that it will...
GlobeNewswire · 05/18 12:00
iBio quarterly net loss widens 61% even as revenue shows strong gain
IBio's (NYSE:IBIO) Q1 2022 net loss widened 61% to $12.4M (-$0.06 per share) despite a ~155% year-over-year revenue increase. Revenue of ~$1.9M in the quarter compared to $765K in the
Seekingalpha · 05/13 16:55
iBio: Q3 Earnings Insights
iBio (AMEX:IBIO) reported its Q3 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings iBio missed estimated earnings by 20.0%, reporting an EPS of $-0.06 versus an estimate of $-0.05.
Benzinga · 05/12 22:37
iBio GAAP EPS of -$0.06 in-line, revenue of $1.94M beats by $1.74M
iBio press release (NYSE:IBIO): Q3 GAAP EPS of -$0.06 in-line. Revenue of $1.94M (+155.3% Y/Y) beats by $1.74M. CEO comment: “We anticipate there may be a notable medical and business
Seekingalpha · 05/12 20:07
-- Earnings Flash (IBIO) IBIO Reports Q3 Revenue $1.9M
MT Newswires · 05/12 16:23
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
iBio FQ3 2022 Earnings Preview
iBio (NYSE:IBIO) is scheduled to announce FQ3 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.06 (-50.0% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 05/11 21:35
Earnings Outlook For iBio
iBio (AMEX:IBIO) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that iBio will report an earnings per share (EPS) of $-0.05.
Benzinga · 05/11 16:08
iBio cancer drug candidate IBIO-101 shows efficacy in preclinical trial
iBio (NYSE:IBIO) said on Monday preclinical data evaluating its cancer drug candidate IBIO-101 showed equal efficacy and potency compared with IL-2 sparing anti-CD25 antibody. The company's therapy, IBIO-101, is produced with its
Seekingalpha · 05/09 13:17
iBio Demonstrates Efficacy Of An IL-2 Sparing Anti-CD25 Antibody Produced Using Its FastPharming System For Treg Depletion In Cancer
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, announced
Benzinga · 05/09 12:17
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made MoleculeNEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a ...
GlobeNewswire · 05/09 12:00
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will...
GlobeNewswire · 05/05 20:30
iBio Highlights Poster Presentation for 'Plant-Made Antibodies Show Superior Glycosylation Homogeneity While Retaining Pharmacokinetic Properties' At Annual Protein & Antibody Engineering Summit May 2-5
Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- iBio,
Benzinga · 05/02 12:11
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer o...
GlobeNewswire · 05/02 12:00
22 Stocks Moving in Friday's Pre-Market Session
Gainers Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading. Moving iMage Technologies and SNDBX reported a strategic partnership for gaming and e-Sports.
Benzinga · 04/22 09:56
26 Stocks Moving in Thursday's Pre-Market Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday.
Benzinga · 04/21 10:22
iBio extends recent gains; Can the rally continue?
iBio (NYSE:IBIO), a development-stage biotech with operations in contract development, is trading higher for the third straight session triggering concerns how long the rally will last amid a major bearish
Seekingalpha · 03/24 19:24
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its C...
GlobeNewswire · 03/11 13:00
24 Stocks Moving in Friday's Pre-Market Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 30.4% to $0.9520 in pre-market trading. Statera Biopharma recently submitted Phase 1 clinical trial protocol to the FDA for investigational treatment of long-haul COVID-19.
Benzinga · 03/04 11:48
More
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about Ibio through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a developer of biopharmaceuticals and FastPharming Manufacturing System. The Company is applying its technologies to develop product candidates to treat or prevent fibrotic diseases, cancers, and infectious diseases. The Company is using its FastPharming Manufacturing System (FastPharming System) and Glycaneering Services to build a portfolio of biologic drug candidates. The Company is also using the FastPharming System to create proteins for others by contract through the Company’s catalog. The Company operates through two segments: Biopharmaceuticals and Bioprocessing. Its Biopharmaceuticals segment, which includes development and licensing in two business units: therapeutics and vaccines. Its Bioprocessing, which includes services and products for research and further manufacturing uses, collectively known as Research & Bioprocess products (RBP). Its pipeline includes IBIO-100, IBIO-101, IBIO-202 and IBIO-400.